Immunoassay for Neurological Biomarkers Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Immunoassay for Neurological Biomarkers Market Overview

The Immunoassay for Neurological Biomarkers market reached a value of approximately USD 650.18 Million in 2025. The market is witnessing steady growth, driven by the rising prevalence of neurodegenerative disorders, increasing demand for early and accurate disease diagnosis, and continuous advancements in immunoassay technologies. Growing adoption of biomarker-based testing in clinical diagnostics and neurological research is improving disease detection and patient management. Expanding investments in precision medicine, increasing pharmaceutical research on neurological disorders, and the development of highly sensitive immunoassay platforms are further supporting market expansion. Favorable regulatory initiatives and enhanced laboratory capabilities continue to accelerate adoption across healthcare and research settings.

Immunoassay for Neurological Biomarkers Market Growth Analysis and Key Influencers

Immunoassay for Neurological Biomarkers Market Dynamics

This section analyzes factors influencing the market, including growth drivers, market restraints, emerging opportunities, technological advancements, biomarker discoveries, regulatory developments, diagnostic innovations, and evolving clinical applications in neurological disease management.

Immunoassay for Neurological Biomarkers Market Growth Drivers

Rising Diagnostic Innovation to Propel the Market Demand

Increasing neurological disease prevalence, expanding clinical validation, and growing demand for minimally invasive diagnostics are expected to accelerate market expansion. For instance, in January 2026, Fujirebio launched the fully automated Lumipulse® G pTau 217 CSF assay for research use, expanding its neurological biomarker portfolio for Alzheimer's disease. The launch enhances laboratory testing capabilities and supports broader biomarker adoption, strengthening market growth throughout the forecast period.

Immunoassay for Neurological Biomarkers Market Restraints

Confirmatory Testing Requirements Continue Constraining Market Expansion Across the Market

Stringent clinical validation requirements and concerns regarding diagnostic specificity continue to challenge wider commercialization. For instance, in June 2025, reports following the adoption of FDA-cleared Alzheimer's blood tests highlighted that positive results still require confirmatory imaging or cerebrospinal fluid testing because biomarker levels may vary under certain physiological conditions. These limitations may moderate clinical adoption, influencing market restraints despite technological progress.

Immunoassay for Neurological Biomarkers Market Opportunities

Strategic Collaborations Enhance Market Value Through Advanced Biomarker Commercialization Initiatives

Growing strategic collaborations and increasing investment in blood-based biomarker development are expected to create new commercial opportunities. For instance, in March 2026, Fujirebio completed the integration of ADx NeuroSciences into its European operations, expanding neurological biomarker expertise and accelerating assay development capabilities. The strengthened R&D infrastructure is anticipated to support innovative immunoassay commercialization, creating significant market opportunities during the forecast period.

Immunoassay for Neurological Biomarkers Market Trends

Minimally Invasive Testing Transform Market Landscape with Emerging Testing Technologies

Growing demand for minimally invasive testing and wider laboratory automation is shaping market trends in neurological biomarker immunoassays. For instance, in March 2026, Siemens Healthineers launched its brain health research portfolio with fully automated Atellica IM pTau217 and brain-derived tau assays for research use. Designed for Atellica analyzers, these blood-based chemiluminescent immunoassays enable quantitative biomarker measurement and are expected to support neurological research, assay validation, and future clinical testing expansion across laboratories and research institutions worldwide.

Immunoassay for Neurological Biomarkers Market Share

In Vitro Diagnostics Likely to Dominate the Market Segment by Application

In vitro diagnostics held approximately 63% market share in the historical period and the segment is likely to dominate throughout the forecast period. Increasing demand for minimally invasive neurological biomarker testing, expanding clinical adoption of immunoassays, and continuous improvements in assay sensitivity support sustained utilization. Growing emphasis on early disease detection and standardized laboratory workflows further strengthens this segment's position across healthcare settings, reinforcing the importance of the market in advancing neurological diagnostics.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Immunoassay for Neurological Biomarkers Market Analysis by Region

North America held approximately 41% market share in the historical period and the region is likely to dominate during the forecast period. Strong healthcare infrastructure, widespread availability of advanced diagnostic technologies, robust research investments, and increasing adoption of neurological biomarker testing continue to support regional leadership. The presence of major industry participants and well-established clinical laboratory networks further enhances market expansion, strengthening the market across the region.

Leading Players in the Immunoassay for Neurological Biomarkers Market

Immunoassay for Neurological Biomarkers Market Segmentation

Read more about this report - Request a Free Sample

Key Questions Answered in the Immunoassay for Neurological Biomarkers Market Report

• What was the immunoassay for neurological biomarkers market value in 2025?
• What is the immunoassay for neurological biomarkers market forecast outlook for 2026-2035?
• What major factors aid the demand for the immunoassay for neurological biomarkers market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major immunoassay for neurological biomarkers market trends?
• Which product type segment is expected to dominate the market?
• Which disease type segment is expected to hold the largest market share?
• Which application is expected to account for the highest market share?
• Who are the key players in the immunoassay for neurological biomarkers market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with neurologists, laboratory directors, diagnostic manufacturers, biomarker researchers, regulatory experts, and clinical laboratory professionals specializing in neurological immunoassay technologies.
• Secondary Research: Sources included FDA publications, company press releases, scientific journals, regulatory databases, investor presentations, peer-reviewed literature, and reputable healthcare news portals.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.